Clinical trials: Mental Disorder
Schizophrenia
Pharmacokinetic Properties of Various Modified Release Tablet Formulations of Lu AF11167
The purpose of this study is to investigate the pharmacokinetic (PK) properties of various modified release tablet formulations of Lu AF11167 (Part A) and to investigate the pharmacokinetic (PK) properties of a modified release…
- Trial name
- NCT02260830
- Testing
- Lu AF11167
- Where
- United Kingdom
- Volunteers
- 28 people, healthy volunteers welcome
- Sponsor
- H. Lundbeck A/S
Schizophrenia
A Study of the Safety, PK, and Exploratory Efficacy of SP-624 in Acutely Psychotic Adult Subjects With Schizophrenia
This is a Phase 1B clinical study evaluating the safety and exploring the effectiveness of SP-624 as compared to placebo in the treatment of adults with schizophrenia experiencing acute psychosis.
- Trial name
- NCT04510298
- Testing
- SP-624
- Where
- 2 sites in United States
- Volunteers
- 27 people
- Sponsor
- Sirtsei Pharmaceuticals, Inc.
Depression, Postpartum, Postpartum Depression (PPD)
Brexanolone Lifting Outcomes Of Moms
The purpose of this research study is to test the study drug, LPCN 1154A, as a possible treatment for postpartum depression (PPD).
- Conditions
- Depression, Postpartum, Postpartum Depression (PPD), Post-partum Depression, Postnatal Depression
- Trial name
- BLOOM (NCT07822321)
- Testing
- LPCN 1154A
- Where
- 16 sites in United States
- Volunteers
- 120 people
- Sponsor
- Lipocine Inc.
Memory Dysfunction, Mood Disorders
To Access the Effect of Brain Pill™ on Working Memory Capacity and Mood Behaviour.
Brain Pill™ is a mental health enhancing and successfully marketed dietary supplement.
- Trial name
- NCT03198936
- Testing
- Cognizin® SynapsaTM
- Where
- India
- Volunteers
- 80 people, healthy volunteers welcome
- Sponsor
- Vedic Lifesciences Pvt. Ltd.
Anxiety, Depression
NeuroGlove Anxiety and Depression Study
This is a prospective, homebased, interventional clinical study containing 10 subjects who will be enrolled. Approximately 10 (10) subjects with active anxiety and depression symptoms will receive treatment using the NeuroGlove.
- Conditions
- Anxiety, Depression, Anxiety Depression, Depression, Anxiety
- Trial name
- NCT06065787
- Testing
- NeuroGlove
- Where
- United States
- Volunteers
- 10 people
- Sponsor
- NeuroGlove LLC
Obesity; Endocrine, Hormone Disturbance
Data Mining: Precision Analytical Retrospective Data Correlation
Data from previously analyzed clinical samples tested by Precision Analytical, Inc. will be mined to identify and select samples from patients reporting hormone supplement use.
- Trial name
- NCT04305093
- Where
- United States
- Volunteers
- 144,561 people
- Sponsor
- Precision Analytical, Inc.
Substance Dependence
EtOH Interaction Study
This study will investigate the possible effects of alcohol in combination with GSK598809 on the central nervous system in 20 healthy male and female volunteers, between 18 and 65 years of age.
- Trial name
- NCT00887367
- Testing
- GSK598809, Ethanol
- Where
- Netherlands
- Volunteers
- 20 people, healthy volunteers welcome
- Sponsor
- GlaxoSmithKline
Opioid-Induced Constipation
Assessment of Efficacy and Safety in Relieving Opioid-induced Constipation in Patients With Cancer-related Pain
The purpose of this study is to compare the effect of NKTR-118 with placebo in the treatment of opioid-induced constipation (OIC) in patients with cancer-related pain, including those patients that have inadequate response to…
- Trial name
- NCT01384292
- Testing
- NKTR-118
- Where
- 140 sites in United States, Australia and 12 more
- Volunteers
- 14 people
- Sponsor
- AstraZeneca
Schizophrenia
A Clinical Trial of Lurasidone in Treatment of Schizophrenia
This is a randomized, double-blind, double-dummy, parallel- controlled, adjustable dose, non-inferiority and multicentre study designed to evaluate the efficacy and safety of lurasidone on schizophrenia for 6 weeks treatment, and…
- Trial name
- NCT02002832
- Testing
- Lurasidone tablets, Risperidone tablets
- Where
- 15 sites in China
- Volunteers
- 388 people
- Sponsor
- Marubeni Pharmaceuticals (Suzhou) Co., Ltd.
Major Depressive Disorder
Safety and Efficacy of Cariprazine as an Adjunctive to Antidepressant Therapy in Major Depressive Disorder
An outpatient study to evaluate the safety and efficacy of cariprazine as adjunct to antidepressant therapy (ADT) in participants with major depressive disorder (MDD) who have an inadequate response to ADT alone.
- Trial name
- NCT01469377
- Testing
- Cariprazine
- Where
- 72 sites in United States, Estonia and 4 more
- Volunteers
- 819 people
- Sponsor
- Forest Laboratories
Alzheimer's Disease
A Randomized, Placebo-Controlled Trial to Examine the Efficacy of Oral Donepezil in Subjects With MCI
To purpose of this study is to estimate the effect of donepezil on Neuropsychological Testing (NPT) and brain Proton Magnetic Resonance Spectroscopy.
- Trial name
- NCT00483028
- Testing
- donezepil (Aricept)
- Where
- 2 sites in United States
- Volunteers
- 38 people, healthy volunteers welcome
- Sponsor
- Pfizer
Depressive Disorder, Major
A Study to Test Different Doses of BI 1569912 in People With Depression
This study is open to adults between 18 and 65 years of age with a type of depression called major depressive disorder. The purpose of the study is to find out whether a medicine called BI 1569912 helps people with depression.
- Trial name
- NCT06558344
- Testing
- 5 mg BI 1569912, 10 mg BI 1569912, 20 mg of BI 1569912
- Where
- 41 sites in United States, Japan
- Volunteers
- 225 people
- Sponsor
- Boehringer Ingelheim
Alzheimer's Disease
18-months Safety Follow-up Study of AADvac1, an Active Tau Vaccine for Alzheimer's Disease
This follow-up study continues to observe patients who have completed the phase 1 trial of AADvac1, for another 18 months. Long-term safety and behavior of the immune response to AADvac1 over time are the main points of interest.
- Trial name
- FUNDAMANT (NCT02031198)
- Testing
- AADvac1
- Where
- 4 sites in Austria
- Volunteers
- 25 people
- Sponsor
- Axon Neuroscience SE
Alzheimer's Disease
Effects of ONO-2506PO in Patients With Alzheimer's Disease
The purpose of this study is to establish the presence of an effect of treatment with ONO-2506PO in patients with Alzheimer's Disease, based upon cognitive and global scales.
- Trial name
- NCT00083421
- Testing
- ONO-2506PO
- Where
- 87 sites in United States, Canada
- Volunteers
- 647 people
- Sponsor
- Ono Pharma USA Inc
Alzheimer's Disease
Clinical Trial of CT1812 in Mild to Moderate Alzheimer's Disease
This is a multi-center, randomized, double-blind, placebo-controlled, parallel group study of two doses of CT1812 in adults with mild to moderate Alzheimer's Disease to evaluate the safety and tolerability of oral CT1812…
- Trial name
- NCT02907567
- Testing
- CT1812
- Where
- 4 sites in Australia
- Volunteers
- 19 people
- Sponsor
- Cognition Therapeutics
Cognitive Functions Perceptual Disturbances, Cognitive Function Abnormal
Effect of ExoBDNF Lactic Acid Bacteria Supplement on Cognitive Functions, Sleep and Psychological
This open-label, single-group, pre/post-test clinical study was conducted to investigate whether ExoBDNF probiotic supplementation could improve cognitive ability.
- Conditions
- Cognitive Functions Perceptual Disturbances, Cognitive Function Abnormal, Sleep, Psychological
- Trial name
- NCT06968299
- Testing
- ExoBDNF SWP-CGPA01 (Pediococcus acidilactici)Capsules
- Where
- Taiwan
- Volunteers
- 50 people, healthy volunteers welcome
- Sponsor
- SunWay Biotech Co., LTD.
Depression, Anxiety
Focused Ultrasound for Behavioral Health
This is a double-blind, within-participant crossover, multi-site dose-finding study evaluating the safety, feasibility, and preliminary efficacy of repeated low-intensity focused ultrasound (LIFU) stimulation using the ATTN201…
- Conditions
- Depression, Anxiety, Obsessive Compulsive Disorder (OCD)
- Trial name
- VANTUS (NCT07851038)
- Testing
- ATTN201 head-worn focused ultrasound
- Where
- 2 sites in United States
- Volunteers
- 300 people
- Sponsor
- Attune Neurosciences Inc
Schizophrenia
An Efficacy, Safety And Tolerability Study of Flexibly Dosed Paliperidone Extended Release (ER) in Participants With Schizophrenia
The purpose of this study is to explore tolerability, safety and effectiveness of flexibly dosed paliperidone extended release (ER) in participants with schizophrenia (psychiatric disorder with symptoms of emotional instability…
- Trial name
- PERFlexS (NCT00460512)
- Testing
- Paliperidone ER
- Where
- 231 sites in Belgium, Bulgaria and 20 more
- Volunteers
- 1,814 people
- Sponsor
- Janssen-Cilag International NV
Memory Disorders, Alzheimer Disease
Evaluation of a Handheld Event Related Potential (ERP)/Quantitative Electroencephalography (qEEG) System (COGNISION™) as a Useful Cognitive Biomarker for Alzheimer's Disease.
The proposed study is designed to evaluate the performance of the COGNISION™ System as a tool to assist physicians in diagnosing Alzheimer's Disease (AD) in real-world clinical settings.
- Conditions
- Memory Disorders, Alzheimer Disease, Dementia, Cognitive Impairment
- Trial name
- COGNISION™ (NCT00938665)
- Testing
- COGNISION™ System
- Where
- 7 sites in United States
- Volunteers
- 204 people, healthy volunteers welcome
- Sponsor
- Neuronetrix, Inc.
Schizophrenia
A Clinical Study That Will Assess the Effect of SEP-363856 or Prior Antipsychotic (PA) Standard of Care on Body-weight Associated Parameters in Subjects With Schizophrenia
A Clinical Study that will look at an investigational medication, SEP-363856 (called "study medication") in patients with schizophrenia, and assess wether it affectsbody-weight associated parameters.
- Trial name
- NCT05542264
- Testing
- SEP-363856, Prior antipsychotic (risperidone, olanzapine, quetiapine or aripiprazole)
- Where
- 4 sites in United States
- Volunteers
- 19 people
- Sponsor
- Otsuka Pharmaceutical Development & Commercialization, Inc.
The first 1,020 results can be paged through. Add a filter or change the sort order to reach the rest.